...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: AACR

Yes, a poor cash period.
They need to preserve whatever cash they have as I see it.

Looking at the Jan 31st Financial Statement, they are low in cash.  Could be several reasons why they aren't attending those conferences which might include limiting discretionary expenses in the short term until their cash position changes.

Share
New Message
Please login to post a reply